Decline of programmed death-1-positive circulating T regulatory cells predicts more favourable clinical outcome of patients with melanoma under immune checkpoint blockade.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
accepted:
24
07
2019
pubmed:
31
7
2019
medline:
15
5
2021
entrez:
31
7
2019
Statut:
ppublish
Résumé
The role of T regulatory lymphocytes (Tregs) and their immunosuppressive mechanisms in the context of programmed death (PD)-1 blockade is not completely understood. To assess the impact of PD-1-blocking antibody treatment on Treg subpopulations in the blood. We studied circulating Treg subpopulations in patients with melanoma under nivolumab or pembrolizumab treatment using flow cytometry and correlated these findings with clinical outcomes. These analyses revealed that the frequency of CD4 We provide preliminary evidence that circulating PD-1
Sections du résumé
BACKGROUND
The role of T regulatory lymphocytes (Tregs) and their immunosuppressive mechanisms in the context of programmed death (PD)-1 blockade is not completely understood.
OBJECTIVES
To assess the impact of PD-1-blocking antibody treatment on Treg subpopulations in the blood.
METHODS
We studied circulating Treg subpopulations in patients with melanoma under nivolumab or pembrolizumab treatment using flow cytometry and correlated these findings with clinical outcomes.
RESULTS
These analyses revealed that the frequency of CD4
CONCLUSIONS
We provide preliminary evidence that circulating PD-1
Substances chimiques
Immune Checkpoint Inhibitors
0
Programmed Cell Death 1 Receptor
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1214-1220Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2019 British Association of Dermatologists.
Références
Schadendorf D, van Akkooi ACJ, Berking C et al. Melanoma. Lancet 2018; 392:971-84.
Leung CS, Yang KY, Li X et al. Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells. Genome Med 2018; 10:71.
Marconcini R, Spagnolo F, Stucci LS et al. Current status and perspectives in immunotherapy for metastatic melanoma. Oncotarget 2018; 9:12452-70.
Correll A, Tuettenberg A, Becker C, Jonuleit H. Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination. Exp Dermatol 2010; 19:e213-21.
McCarter MD, Baumgartner J, Escobar GA et al. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol 2007; 14:2854-60.
Gambichler T, Bindsteiner M, Höxtermann S et al. Circulating CD4+ CD25high CD127low regulatory T cells are an independent predictor of advanced melanoma. Pigment Cell Melanoma Res 2013; 26:280-3.
Kähler KC, Hassel JC, Heinzerling L et al. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges 2016; 14:662-81.
Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol 2016; 27:1492-504.
Kumar S, Malik S, Singh UP et al. PD-1 expression on Foxp3+ Treg cells modulates CD8+ T cell function in prostatic tumor microenvironment. J Immunol 2017; 198 (Suppl. 1):155.11.
Syed Khaja AS, Toor SM, El Salhat H et al. Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. Oncotarget 2017; 8:33159-71.
Kim HR, Park HJ, Son J et al. Upregulation of immune checkpoint molecules on Treg cells in tumor microenvironment reinforces immune exhaustion in cancer patients. Cancer Res 2018; 78 (13 Suppl.):Abstr. 713.
Shi T, Ma Y, Yu L et al. Cancer immunotherapy: a focus on the regulation of immune checkpoints. Int J Mol Sci 2018; 19:E1389.
Lowther DE, Goods BA, Lucca LE et al. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. JCI Insight 2016; 1:e85935.
van de Ven R, Niemeijer AN, Stam AGM et al. High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes. ERJ Open Res 2017; 3:00110-2016.
Wang W, Lau R, Yu D et al. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25Hi regulatory T cells. Int Immunol 2009; 21:1065-77.
Wu SP, Liao RQ, Tu HY et al. Stromal PD-L1-positive regulatory T cells and PD-1-positive CD8-positive T cells define the response of different subsets of non-small cell lung cancer to PD-1/PD-L1 blockade immunotherapy. J Thorac Oncol 2018; 13:521-32.
Gambichler T, Schröter U, Höxtermann S et al. A brief communication on circulating PD-1-positive T-regulatory lymphocytes in melanoma patients undergoing adjuvant immunotherapy with nivolumab. J Immunother 2019; 42:265-8.
Lugowska I, Teterycz P, Rutkowski P. Immunotherapy of melanoma. Contemp Oncol (Pozn) 2018; 22:61-7.
Wang X, Bao Z, Zhang X et al. Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. Oncotarget 2017; 8:59901-14.
Yuasa T, Masuda H, Yamamoto S et al. Biomarkers to predict prognosis and response to checkpoint inhibitors. Int J Clin Oncol 2017; 22:629-34.
Kitano S, Nakayama T, Yamashita M. Biomarkers for immune checkpoint inhibitors in melanoma. Front Oncol 2018; 8:270.
Nobashi T, Baratto L, Reddy SA et al. Predicting response to immunotherapy by evaluating tumors, lymphoid cell-rich organs, and immune-related adverse events using FDG-PET/CT. Clin Nucl Med 2019; 44:e272-9.
Saleh K, Khalife-Saleh N, Kourie HR. Do immune-related adverse events correlate with response to immune checkpoint inhibitors? Immunotherapy 2019; 11:257-9.